[Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris].

AIM: Assessment of effects of a 3-month course of atorvastatin and a nicotinic acid derivative acipimox on the lipid spectrum, platelet aggregation, results of brachial artery reactive hyperemia test and clinical outcomes in patients with unstable angina pectoris (UAP). MATERIAL AND METHODS: A total of 109 males with new-onset and progressive UAP entered the trial. They had LDLP cholesterol > or = 115 mg/dl. RESULTS: The addition of atorvastatin to combined therapy of UAP patients resulted in achievement of a target level of LDLP cholesterol level in 64% dose-adjusted patients while in acipimox patients the target level was achieved in 20% patients. In spite of a more potent effect on endothelial function, acipimox had an insignificant effect on the treatment outcomes. CONCLUSION: Hypolipidemic therapy with atorvastatin and acipimox for UAP leads to a significant reduction in LDLP cholesterol. The effect of atorvastatin comes much earlier and more frequently provides a target level of LDLP cholesterol.

[The effect of verapamil on the course of stenocardia of effort, on the blood serum lipid level and on the basic indices of carbohydrate metabolism during the long-term use of the preparation]. / Vliianie verapamila na techenie stenokardii napriazheniia, soderzhanie lipidov syvorotki krovi i osnovnye pokazateli uglevodnogo obmena pri dlitel'nom primenenii preparata.

The therapeutical efficiency of verapamil given for 3 months was studied in 36 patients with stable exercise-induced angina by multistep gradually increasing bicycle ergometry exercise test. The effects of the agent on serum lipid levels were evaluated in 30 cases. The therapeutical effect was achieved in 24 patients; verapamil caused a pronounced increase in physical working capacity just during the acute drug test in all cases and showing growing effects within a month of treatment. No increase in therapeutical effects was observed in 12 cases in whom a rise in exercise time was insignificant during the acute drug test. Verapamil produced no noticeable effect on fasting serum glucose and insulin levels after glucose tolerance test in 19 healthy individuals and 11 patients with lower carbohydrate tolerance. Thirteen patients with primary hypercholesterolemia had decreased levels of total cholesterol due to low density lipoprotein cholesterol.